1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS
申请人:Rano Thomas
公开号:US20070265304A1
公开(公告)日:2007-11-15
The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
Design, Synthesis, and Biological Evaluation of (2<i>R</i>,α<i>S</i>)-3,4-Dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-α-(trifluoromethyl)-1(2<i>H</i>)-quinolineethanol as Potent and Orally Active Cholesteryl Ester Transfer Protein Inhibitor
作者:Gee-Hong Kuo、Thomas Rano、Patricia Pelton、Keith T. Demarest、Alan C. Gibbs、William V. Murray、Bruce P. Damiano、Margery A. Connelly
DOI:10.1021/jm801319d
日期:2009.3.26
With the goal of identifying a CETP inhibitor with high in vitro potency and optimal in vivo efficacy, a conformationally constrained molecule was designed based on the highly potent and flexible 13. The synthetic chemistry efforts led to the discovery of the potent and selective 12. In high-fat fed hamsters, human CETP transgenic mice, and cynomolgus monkeys, the in vivo efficacy of 12 for raising HDL-C was demonstrated to be comparable to torcetrapib.
US7928238B2
申请人:——
公开号:US7928238B2
公开(公告)日:2011-04-19
[EN] 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS<br/>[FR] DÉRIVÉS DE 1,2,3,4-TÉTRAHYDRO-QUINOLINE EN TANT QU'INHIBITEURS DE LA CETP
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2008079427A1
公开(公告)日:2008-07-03
[EN] The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them. [FR] La présente invention concerne des composés de formule (I) décrits ici comme étant utiles en tant qu'inhibiteurs de la CETP, des compositions les contenant, et des procédés pour les utiliser.
Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform
作者:Thomas A. Rano、Ellen Sieber-McMaster、Patricia D. Pelton、Maria Yang、Keith T. Demarest、Gee-Hong Kuo
DOI:10.1016/j.bmcl.2009.03.051
日期:2009.5
a potent inhibitor of the cholesterol ester transfer protein (CETP), a target for the treatment of low HDL-C and atherosclerosis. Low HDL-C has been identified as a key risk factor for cardiovascular disease in addition to high LDL-C, the target of the statin drugs. Tetrahydroquinoline A inhibits partially purified CETP with an IC50 of 39 nM. The preparation of a series of potent inhibitors of CETP